Beta Bionics, Inc. logo BBNX - Beta Bionics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 6
HOLD 2
SELL 0
STRONG
SELL
0
| PRICE TARGET: $21.00 DETAILS
HIGH: $25.00
LOW: $14.00
MEDIAN: $22.00
CONSENSUS: $21.00
UPSIDE: 77.66%

About Beta Bionics, Inc. (https://www.betabionics.com)

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Key Executives

NAME TITLE DOB SALARY
Sean T. Saint President, Chief Executive Officer & Director 1976 $1,625,600 USD
Stephen H. Feider Chief Financial Officer, Treasurer & Secretary 1990 $832,378 USD
Mike Mensinger Chief Product Officer 1978 $789,556 USD
Mark Hopman Chief Commercial Officer 1978 $559,533 USD
Blake Beber Head of Investor Relations
David Henderson Vice President of Operations
Kevin Meinert Vice President of Legal & Business Development
Steven Russell Chief Medical Officer 1969

Company Peers

Peer analysis pending, check back in 1-2 minutes.